Watkins H, McKenna W J, Thierfelder L, Suk H J, Anan R, O'Donoghue A, Spirito P, Matsumori A, Moravec C S, Seidman J G
Howard Hughes Medical Institute, Boston, MA.
N Engl J Med. 1995 Apr 20;332(16):1058-64. doi: 10.1056/NEJM199504203321603.
Familial hypertrophic cardiomyopathy can be caused by mutations in the genes for beta cardiac myosin heavy chain, alpha-tropomyosin, or cardiac troponin T. It is not known how often the disease is caused by mutations in the tropomyosin and troponin genes, and the associated clinical phenotypes have not been carefully studied.
Linkage between polymorphisms of the alpha-tropomyosin gene or the cardiac troponin T gene and hypertrophic cardiomyopathy was assessed in 27 families. In addition, 100 probands were screened for mutations in the alpha-tropomyosin gene, and 26 were screened for mutations in the cardiac troponin T gene. Life expectancy, the incidence of sudden death, and the extent of left ventricular hypertrophy were compared in patients with different mutations.
Genetic analyses identified only one alpha-tropomyosin mutation, identical to one previously described. Five novel mutations in cardiac troponin were identified, as well as a further example of a previously described mutation. The clinical phenotype of four troponin T mutations in seven unrelated families was similar and was characterized by a poor prognosis (life expectancy, approximately 35 years) and a high incidence of sudden death. The mean (+/- SD) maximal thickness of the left ventricular wall in subjects with cardiac troponin T mutations (16.7 +/- 5.5 mm) was significantly less than that in subjects with beta cardiac myosin heavy-chain mutations (23.7 +/- 7.7 mm, P < 0.001).
Mutations in alpha-tropomyosin are a rare cause of familial hypertrophic cardiomyopathy, accounting for approximately 3 percent of cases. Mutations in cardiac troponin T account for approximately 15 percent of cases of familial hypertrophic cardiomyopathy in this referral-center population. These mutations are characterized by relatively mild and sometimes subclinical hypertrophy but a high incidence of sudden death. Genetic testing may therefore be especially important in this group.
家族性肥厚型心肌病可由β-心肌肌球蛋白重链、α-原肌球蛋白或心肌肌钙蛋白T基因的突变引起。目前尚不清楚该疾病由原肌球蛋白和肌钙蛋白基因突变引起的频率,且相关的临床表型尚未得到仔细研究。
对27个家族评估α-原肌球蛋白基因或心肌肌钙蛋白T基因的多态性与肥厚型心肌病之间的连锁关系。此外,对100名先证者筛查α-原肌球蛋白基因的突变,对26名先证者筛查心肌肌钙蛋白T基因的突变。比较不同突变患者的预期寿命、猝死发生率和左心室肥厚程度。
基因分析仅鉴定出1个α-原肌球蛋白突变,与先前描述的一个相同。鉴定出5个心肌肌钙蛋白的新突变,以及1个先前描述突变的另一例。7个不相关家族中4个肌钙蛋白T突变的临床表型相似,其特征为预后不良(预期寿命约35岁)和猝死发生率高。心肌肌钙蛋白T突变患者左心室壁的平均(±标准差)最大厚度(16.7±5.5mm)显著小于β-心肌肌球蛋白重链突变患者(23.7±7.7mm,P<0.001)。
α-原肌球蛋白突变是家族性肥厚型心肌病的罕见病因,约占病例的3%。在该转诊中心人群中,心肌肌钙蛋白T突变约占家族性肥厚型心肌病病例的15%。这些突变的特征是肥厚相对较轻,有时为亚临床肥厚,但猝死发生率高。因此,基因检测在该组患者中可能尤为重要。